Abstract
Herein, we describe the synthesis, antiviral structure-activity relationships (SAR), metabolic stability, and pharmacokinetic (PK) properties for a series of cyclopropylindolobenzazepine acylsulfonamide HCV NS5B polymerase inhibitors. Optimization of SAR, metabolic stability and PK led to the identification of compound 19 which was advanced into pre-IND enabling toxicology studies.
Keywords:
Antiviral agent; Cyclopropylindolobenzazepine; Direct-acting; HCV; Inhibitors; NS5B; Replicase.
Copyright © 2015 Elsevier Ltd. All rights reserved.
MeSH terms
-
Administration, Oral
-
Animals
-
Antiviral Agents / chemical synthesis
-
Antiviral Agents / chemistry*
-
Antiviral Agents / pharmacokinetics
-
Benzazepines / chemistry
-
Drug Evaluation, Preclinical
-
Half-Life
-
Hepacivirus / enzymology*
-
Humans
-
Macaca fascicularis
-
Microsomes, Liver / metabolism
-
RNA-Dependent RNA Polymerase / antagonists & inhibitors*
-
RNA-Dependent RNA Polymerase / metabolism
-
Rats
-
Structure-Activity Relationship
-
Sulfonamides / chemical synthesis
-
Sulfonamides / chemistry*
-
Sulfonamides / pharmacokinetics
Substances
-
Antiviral Agents
-
Benzazepines
-
Sulfonamides
-
RNA-Dependent RNA Polymerase